Ultrafast dynamic contrast-enhanced breast MRI with quantitative perfusion parameters in differentiating breast cancer: a study focusing on triple-negative and HER2 positive breast cancer
BackgroundIn the realm of breast cancer diagnosis and treatment, accurately discerning molecular subtypes is of paramount importance, especially when aiming to avoid invasive tests. The updated guidelines for diagnosing and treating HER2 positive advanced breast cancer, as presented at the 2021 Nati...
Saved in:
Main Authors: | Guo Haodong, Zhu Jianguo, Dmytro Pylypenko, Dou Weiqiang, Su Sheng, Xu Jie, Li Haige |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1457918/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs
by: Xiang Zhang, et al.
Published: (2025-02-01) -
Receptor Status Differences in Prognosis for Breast Cancer
by: Yelda Deligöz Bildacı, et al.
Published: (2024-07-01) -
The association of BMI and subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapy
by: Feng Zhang, et al.
Published: (2024-12-01) -
Subtype-specific prognostic impact of Bcl-2 in HER2-positive and HER2-negative breast cancer
by: Taeyeong Kim, et al.
Published: (2025-01-01) -
Exploring the heterogeneity of HER2 gene status and expression in non-positive breast cancer patients: insights from immunohistochemistry and fluorescence in situ hybridization
by: Jingmin Zhong, et al.
Published: (2025-01-01)